No Data
No Data
Staidson: Summary of Half-Year Report in 2024.
Staidson: Half-year report for the year 2024.
Staidson's H1 losses narrowed significantly, is reducing R&D investment a key factor in improving performance? | Interpretations
① Staidson significantly narrowed its net loss in H1, with the reduced research and development costs potentially playing a key role; ② Compared to the same period last year, Staidson has cut off all pipeline related to COVID-19. At the same time, the company's research and development personnel decreased by nearly 60% year-on-year.
Staidson (300204.SZ): the net loss in the first half of the year was 3.423 million yuan
On August 26, Staidson (300204.SZ) announced its 2024 interim report, with revenue of 0.182 billion yuan during the reporting period, a year-on-year growth of 7.69%; net income attributable to shareholders of the listed company was -3.423 million yuan; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -6.374 million yuan; basic earnings per share was -0.01 yuan. During the reporting period, Shu Taiqing achieved sales revenue of 98.99 million yuan, accounting for 54.27% of revenue, an increase of 20.06% compared to the same period last year; Sutai Sheng achieved sales revenue of 78.82 million yuan, accounting for revenue.
Staidson (300204.SZ): The first subject of the Phase I clinical trial of STSP-0902 injection (used to treat oligoasthenozoospermia) has completed dosing.
On August 15th, Gelunhui reported that Staidson (300204.SZ) received the Drug Clinical Trial Approval Notice (Notice No. 2024LP01413) for STSP-0902 Injection for the treatment of asthenozoospermia from the State Food and Drug Administration in June 2024, and was allowed to conduct clinical trials of this product for asthenozoospermia. Recently, the first subject for phase I clinical trial of asthenozoospermia was given STSP-0902 injection at the Third Hospital of Peking University. STSP-0902 is a targeted drug independently developed by Staidson for specific sites.
Staidson (300204.SZ): Currently conducting a phase IIb clinical study on demand treatment of bleeding in hemophilia A or B patients with coagulation inhibitors.
On August 14th, Gelunhui reported that Staidson (300204.SZ) stated on their investor interaction platform that the STSP-0601 project has completed phase Ib/II clinical trials for the treatment of bleeding on demand in hemophilia A or B patients with inhibitors, as well as phase II clinical trials for the treatment of bleeding on demand in hemophilia A or B patients without inhibitors. Currently, phase IIb clinical trials for the treatment of bleeding on demand in hemophilia A or B patients with inhibitors is underway.
No Data